niacinamide has been researched along with Osteonecrosis in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma." | 7.83 | Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016) |
| "Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma." | 3.83 | Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016) |
| "Retrospective study on all the renal cell carcinoma patients with bone metastases treated with sunitinib or sorafenib between November 2005 and June 2012 at the University Hospitals Leuven and AZ Groeninge in Kortrijk." | 3.78 | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. ( Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P, 2012) |
| "Osteonecrosis of the jaw (ONJ) is a rare treatment related side effect that was firstly described in 2002 through a case report in metastatic bone cancer patient treated with bisphosphonates (BPs) therapy." | 2.55 | Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect. ( Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonuzzo, L | 1 |
| Lunghi, A | 1 |
| Petreni, P | 1 |
| Brugia, M | 1 |
| Laffi, A | 1 |
| Giommoni, E | 1 |
| Mela, MM | 1 |
| Mazzoni, F | 1 |
| Balestri, V | 1 |
| Costanzo, FD | 1 |
| Garuti, F | 1 |
| Camelli, V | 1 |
| Spinardi, L | 1 |
| Bucci, L | 1 |
| Trevisani, F | 1 |
| Beuselinck, B | 1 |
| Wolter, P | 1 |
| Karadimou, A | 1 |
| Elaidi, R | 1 |
| Dumez, H | 1 |
| Rogiers, A | 1 |
| Van Cann, T | 1 |
| Willems, L | 1 |
| Body, JJ | 1 |
| Berkers, J | 1 |
| Van Poppel, H | 1 |
| Lerut, E | 1 |
| Debruyne, P | 1 |
| Paridaens, R | 1 |
| Schöffski, P | 1 |
1 review available for niacinamide and Osteonecrosis
| Article | Year |
|---|---|
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phe | 2017 |
3 other studies available for niacinamide and Osteonecrosis
| Article | Year |
|---|---|
Sorafenib: osteonecrosis of the jaw.
Topics: Antineoplastic Agents; Humans; Jaw; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase | 2015 |
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2016 |
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Ca | 2012 |